CD274 and non-small cell lung carcinoma: For instance, durvalumab (anti–PD-L1) and tremelimumab (anti–CTLA-4) have been tested in combination with hypofractionated radiotherapy for NSCLC (Chang et al., 2022; Schoenfeld et al., 2022; Galluzzi et al., 2023), while stereotactic radiotherapy combined with nivolumab and ipilimumab has shown efficacy in Merkel cell carcinoma (Kim et al., 2022).